-
Je něco špatně v tomto záznamu ?
Outcome-Driven Thresholds for Ambulatory Blood Pressure Based on the New American College of Cardiology/American Heart Association Classification of Hypertension
YB. Cheng, L. Thijs, ZY. Zhang, M. Kikuya, WY. Yang, JD. Melgarejo, J. Boggia, FF. Wei, TW. Hansen, CG. Yu, K. Asayama, T. Ohkubo, E. Dolan, K. Stolarz-Skrzypek, S. Malyutina, E. Casiglia, L. Lind, J. Filipovský, GE. Maestre, Y. Imai, K....
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, práce podpořená grantem
Grantová podpora
R01 AG036469
NIA NIH HHS - United States
R03 AG054186
NIA NIH HHS - United States
NLK
Free Medical Journals
od 1979 do Před 1 rokem
Open Access Digital Library
od 1979-01-01
Open Access Digital Library
od 1979-01-01
- MeSH
- ambulantní monitorování krevního tlaku metody MeSH
- Americká kardiologická asociace MeSH
- dospělí MeSH
- hypertenze komplikace diagnóza patofyziologie MeSH
- kardiovaskulární nemoci etiologie patofyziologie MeSH
- krevní tlak fyziologie MeSH
- lidé středního věku MeSH
- lidé MeSH
- rizikové faktory MeSH
- senioři MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Geografické názvy
- Spojené státy americké MeSH
The new American College of Cardiology/American Heart Association guideline reclassified office blood pressure and proposed thresholds for ambulatory blood pressure (ABP). We derived outcome-driven ABP thresholds corresponding with the new office blood pressure categories. We performed 24-hour ABP monitoring in 11 152 participants (48.9% women; mean age, 53.0 years) representative of 13 populations. We determined ABP thresholds resulting in multivariable-adjusted 10-year risks similar to those associated with elevated office blood pressure (120/80 mm Hg) and stages 1 and 2 of office hypertension (130/80 and 140/90 mm Hg). Over 13.9 years (median), 2728 (rate per 1000 person-years, 17.9) people died, 1033 (6.8) from cardiovascular disease; furthermore, 1988 (13.8), 893 (6.0), and 795 (5.4) cardiovascular and coronary events and strokes occurred. Using a composite cardiovascular end point, systolic/diastolic outcome-driven thresholds indicating elevated 24-hour, daytime, and nighttime ABP were 117.9/75.2, 121.4/79.6, and 105.3/66.2 mm Hg. For stages 1 and 2 ambulatory hypertension, thresholds were 123.3/75.2 and 128.7/80.7 mm Hg for 24-hour ABP, 128.5/79.6 and 135.6/87.1 mm Hg for daytime ABP, and 111.7/66.2 and 118.1/72.5 mm Hg for nighttime ABP. ABP thresholds derived from other end points were similar. After rounding, approximate thresholds for elevated 24-hour, daytime, and nighttime ABP were 120/75, 120/80, and 105/65 mm Hg, and for stages 1 and 2, ambulatory hypertension 125/75 and 130/80 mm Hg, 130/80 and 135/85 mm Hg, and 110/65 and 120/70 mm Hg. Outcome-driven ABP thresholds corresponding to elevated blood pressure and stages 1 and 2 of hypertension are similar to those proposed by the current American College of Cardiology/American Heart Association guideline.
Asociación Española Primera de Socorros Mutuos Montevideo Uruguay
Conway Institute of Biomolecular and Biomedical Research University College Dublin Ireland
Department of Hygiene and Public Health Teikyo University School of Medicine Tokyo Japan
Department of Hypertension and Diabetology Hypertension Unit Medical University of Gdańsk Poland
Department of Medicine University of Padua Italy
Faculty of Medicine Charles University Pilsen Czech Republic
Section of Geriatrics Department of Public Health and Caring Sciences Uppsala University Sweden
Steno Diabetes Center Copenhagen Gentofte and Center for Health Capital Region of Denmark Denmark
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19044608
- 003
- CZ-PrNML
- 005
- 20201119140718.0
- 007
- ta
- 008
- 200109s2019 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1161/HYPERTENSIONAHA.119.13512 $2 doi
- 035 __
- $a (PubMed)31378104
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Cheng, Yi-Bang $u From the Center for Epidemiological Studies and Clinical Trials and Center for Vascular Evaluation, Shanghai Institute of Hypertension, Shanghai Key Laboratory of Hypertension, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, China (Y.-B.C., Y.L., J.-G.W.).
- 245 10
- $a Outcome-Driven Thresholds for Ambulatory Blood Pressure Based on the New American College of Cardiology/American Heart Association Classification of Hypertension / $c YB. Cheng, L. Thijs, ZY. Zhang, M. Kikuya, WY. Yang, JD. Melgarejo, J. Boggia, FF. Wei, TW. Hansen, CG. Yu, K. Asayama, T. Ohkubo, E. Dolan, K. Stolarz-Skrzypek, S. Malyutina, E. Casiglia, L. Lind, J. Filipovský, GE. Maestre, Y. Imai, K. Kawecka-Jaszcz, E. Sandoya, K. Narkiewicz, Y. Li, E. O'Brien, JG. Wang, JA. Staessen,
- 520 9_
- $a The new American College of Cardiology/American Heart Association guideline reclassified office blood pressure and proposed thresholds for ambulatory blood pressure (ABP). We derived outcome-driven ABP thresholds corresponding with the new office blood pressure categories. We performed 24-hour ABP monitoring in 11 152 participants (48.9% women; mean age, 53.0 years) representative of 13 populations. We determined ABP thresholds resulting in multivariable-adjusted 10-year risks similar to those associated with elevated office blood pressure (120/80 mm Hg) and stages 1 and 2 of office hypertension (130/80 and 140/90 mm Hg). Over 13.9 years (median), 2728 (rate per 1000 person-years, 17.9) people died, 1033 (6.8) from cardiovascular disease; furthermore, 1988 (13.8), 893 (6.0), and 795 (5.4) cardiovascular and coronary events and strokes occurred. Using a composite cardiovascular end point, systolic/diastolic outcome-driven thresholds indicating elevated 24-hour, daytime, and nighttime ABP were 117.9/75.2, 121.4/79.6, and 105.3/66.2 mm Hg. For stages 1 and 2 ambulatory hypertension, thresholds were 123.3/75.2 and 128.7/80.7 mm Hg for 24-hour ABP, 128.5/79.6 and 135.6/87.1 mm Hg for daytime ABP, and 111.7/66.2 and 118.1/72.5 mm Hg for nighttime ABP. ABP thresholds derived from other end points were similar. After rounding, approximate thresholds for elevated 24-hour, daytime, and nighttime ABP were 120/75, 120/80, and 105/65 mm Hg, and for stages 1 and 2, ambulatory hypertension 125/75 and 130/80 mm Hg, 130/80 and 135/85 mm Hg, and 110/65 and 120/70 mm Hg. Outcome-driven ABP thresholds corresponding to elevated blood pressure and stages 1 and 2 of hypertension are similar to those proposed by the current American College of Cardiology/American Heart Association guideline.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a Americká kardiologická asociace $7 D000572
- 650 _2
- $a krevní tlak $x fyziologie $7 D001794
- 650 _2
- $a ambulantní monitorování krevního tlaku $x metody $7 D018660
- 650 _2
- $a kardiovaskulární nemoci $x etiologie $x patofyziologie $7 D002318
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a hypertenze $x komplikace $x diagnóza $x patofyziologie $7 D006973
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a rizikové faktory $7 D012307
- 651 _2
- $a Spojené státy americké $7 D014481
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Thijs, Lutgarde $u Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Belgium (L.T., Z.-Y.Z., W.-Y.Y., F.-F.W., C.-G.Y., J.A.S.).
- 700 1_
- $a Zhang, Zhen-Yu $u Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Belgium (L.T., Z.-Y.Z., W.-Y.Y., F.-F.W., C.-G.Y., J.A.S.).
- 700 1_
- $a Kikuya, Masahiro $u Department of Hygiene and Public Health, Teikyo University School of Medicine, Tokyo, Japan (M.K., K.A., T.O.).
- 700 1_
- $a Yang, Wen-Yi $u Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Belgium (L.T., Z.-Y.Z., W.-Y.Y., F.-F.W., C.-G.Y., J.A.S.).
- 700 1_
- $a Melgarejo, Jesus D $u Laboratorio de Neurociencias and Instituto de Enfermedades Cardiovasculares, Universidad del Zulia, Maracaibo, Venezuela (J.D.M., G.E.M.).
- 700 1_
- $a Boggia, José $u Centro de Nefrología and Departamento de Fisiopatología, Hospital de Clínicas, Universidad de la República, Montevideo, Uruguay (J.B.).
- 700 1_
- $a Wei, Fang-Fei $u Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Belgium (L.T., Z.-Y.Z., W.-Y.Y., F.-F.W., C.-G.Y., J.A.S.).
- 700 1_
- $a Hansen, Tine W $u Steno Diabetes Center, Copenhagen, Gentofte, and Center for Health, Capital Region of Denmark, Denmark (T.W.H.).
- 700 1_
- $a Yu, Cai-Guo $u Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Belgium (L.T., Z.-Y.Z., W.-Y.Y., F.-F.W., C.-G.Y., J.A.S.).
- 700 1_
- $a Asayama, Kei $u Department of Hygiene and Public Health, Teikyo University School of Medicine, Tokyo, Japan (M.K., K.A., T.O.). Department of Planning for Drug Development and Clinical Evaluation, Tohoku Institute for Management of Blood Pressure, Sendai, Japan (K.A., T.O., Y.I.).
- 700 1_
- $a Ohkubo, Takayoshi $u Department of Hygiene and Public Health, Teikyo University School of Medicine, Tokyo, Japan (M.K., K.A., T.O.). Department of Planning for Drug Development and Clinical Evaluation, Tohoku Institute for Management of Blood Pressure, Sendai, Japan (K.A., T.O., Y.I.).
- 700 1_
- $a Dolan, Eamon $u Stroke and Hypertension Unit, Blanchardstown, Dublin, Ireland (E.D.).
- 700 1_
- $a Stolarz-Skrzypek, Katarzyna $u First Department of Cardiology, Interventional Electrocardiology and Hypertension, Jagiellonian University Medical College, Krakow, Poland (K.S.-S., K.K.-J).
- 700 1_
- $a Malyutina, Sofia $u Institute of Internal and Preventive Medicine, Institute of Cytology and Genetics, Siberian Branch of the Russian Academy of Sciences, Novosibirsk, Russian Federation (S.M.).
- 700 1_
- $a Casiglia, Edoardo $u Department of Medicine, University of Padua, Italy (E.C.).
- 700 1_
- $a Lind, Lars $u Section of Geriatrics, Department of Public Health and Caring Sciences, Uppsala University, Sweden (L.L.).
- 700 1_
- $a Filipovský, Jan $u Faculty of Medicine, Charles University, Pilsen, Czech Republic (J.F.).
- 700 1_
- $a Maestre, Gladys E $u Laboratorio de Neurociencias and Instituto de Enfermedades Cardiovasculares, Universidad del Zulia, Maracaibo, Venezuela (J.D.M., G.E.M.). Department of Neurosciences and Department of Human Genetics, University of Texas Rio Grande Valley School of Medicine, Brownsville (G.E.M.).
- 700 1_
- $a Imai, Yutaka $u Department of Planning for Drug Development and Clinical Evaluation, Tohoku Institute for Management of Blood Pressure, Sendai, Japan (K.A., T.O., Y.I.).
- 700 1_
- $a Kawecka-Jaszcz, Kalina $u First Department of Cardiology, Interventional Electrocardiology and Hypertension, Jagiellonian University Medical College, Krakow, Poland (K.S.-S., K.K.-J).
- 700 1_
- $a Sandoya, Edgardo $u Asociación Española Primera de Socorros Mutuos, Montevideo, Uruguay (E.S.).
- 700 1_
- $a Narkiewicz, Krzysztof $u Department of Hypertension and Diabetology, Hypertension Unit, Medical University of Gdańsk, Poland (K.N.).
- 700 1_
- $a Li, Yan $u From the Center for Epidemiological Studies and Clinical Trials and Center for Vascular Evaluation, Shanghai Institute of Hypertension, Shanghai Key Laboratory of Hypertension, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, China (Y.-B.C., Y.L., J.-G.W.).
- 700 1_
- $a O'Brien, Eoin $u Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Ireland (E.O.).
- 700 1_
- $a Wang, Ji-Guang $u From the Center for Epidemiological Studies and Clinical Trials and Center for Vascular Evaluation, Shanghai Institute of Hypertension, Shanghai Key Laboratory of Hypertension, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, China (Y.-B.C., Y.L., J.-G.W.).
- 700 1_
- $a Staessen, J. A. $7 xx0254041 $u Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Belgium (L.T., Z.-Y.Z., W.-Y.Y., F.-F.W., C.-G.Y., J.A.S.). Cardiovascular Research Institute Maastricht, Maastricht University, the Netherlands (J.A.S.).
- 773 0_
- $w MED00002089 $t Hypertension (Dallas, Tex. : 1979) $x 1524-4563 $g Roč. 74, č. 4 (2019), s. 776-783
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31378104 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20200109 $b ABA008
- 991 __
- $a 20201119140645 $b ABA008
- 999 __
- $a ok $b bmc $g 1482877 $s 1083281
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 74 $c 4 $d 776-783 $e 20190805 $i 1524-4563 $m Hypertension $n Hypertension $x MED00002089
- GRA __
- $a R01 AG036469 $p NIA NIH HHS $2 United States
- GRA __
- $a R03 AG054186 $p NIA NIH HHS $2 United States
- LZP __
- $a Pubmed-20200109
